Latest
AI in Saudi Healthcare: From Pilots to Practice in 2026
2026 is Saudi Arabia's Year of AI. What SFDA, SDAIA and PDPL require, which healthcare AI use cases pay back, and how to scale.
Mohamed Essam ·
Read articleCareSync blog
Ideas on branded digital care, growth and compliance
Product updates, regional regulatory notes and operating playbooks from the teams launching white-label health apps across the Gulf and wider MENA.
Health systemHealth Clusters and Value-Based Care in Saudi Arabia: What Providers and Pharma Need to Know
10 of 20 Saudi health clusters have moved to Health Holding. What value-based care and capitation mean for providers and pharma.Read article
Patient supportPatient Support Programmes in Saudi Arabia: Best Practices for Pharma in 2026
Adherence averages 50%. How Saudi pharma teams design compliant, multimodal Patient Support Programmes that improve persistence and outcomes.Read article
Pharma marketPharma and Biotech Localisation in Saudi Arabia: What the National Biotechnology Strategy Means for Industry
Insulin, vaccines and GLP-1s are being made in Saudi Arabia. What the National Biotechnology Strategy means for pharma market access.Read article
EvidenceHow Technology Improves Medication Adherence and Patient Outcomes: The Evidence
Text reminders and apps roughly double adherence; remote care lowers HbA1c. How Saudi providers and pharma can apply the evidence.Read article
Connected careConnected Care in Saudi Arabia: What EY's 2026 Data Means for Hospitals and Pharma
Saudi patients track their health and trust clinicians. Explore EY's 2026 findings and a connected-care playbook for providers and pharma.Read article
Patient supportGLP-1s, AI and the Informed Patient: Why Saudi Arabia Needs Continuous Care Now
AI-informed patients and GLP-1 therapies are changing care in Saudi Arabia. See why clinician-led support must continue between appointments.Read article
All
- Healthcare AI
AI in Saudi Healthcare: From Pilots to Practice in 2026
2026 is Saudi Arabia's Year of AI. What SFDA, SDAIA and PDPL require, which healthcare AI use cases pay back, and how to scale.Read article - Health system
Health Clusters and Value-Based Care in Saudi Arabia: What Providers and Pharma Need to Know
10 of 20 Saudi health clusters have moved to Health Holding. What value-based care and capitation mean for providers and pharma.Read article - Patient support
Patient Support Programmes in Saudi Arabia: Best Practices for Pharma in 2026
Adherence averages 50%. How Saudi pharma teams design compliant, multimodal Patient Support Programmes that improve persistence and outcomes.Read article - Pharma market
Pharma and Biotech Localisation in Saudi Arabia: What the National Biotechnology Strategy Means for Industry
Insulin, vaccines and GLP-1s are being made in Saudi Arabia. What the National Biotechnology Strategy means for pharma market access.Read article - Evidence
How Technology Improves Medication Adherence and Patient Outcomes: The Evidence
Text reminders and apps roughly double adherence; remote care lowers HbA1c. How Saudi providers and pharma can apply the evidence.Read article - Connected care
Connected Care in Saudi Arabia: What EY's 2026 Data Means for Hospitals and Pharma
Saudi patients track their health and trust clinicians. Explore EY's 2026 findings and a connected-care playbook for providers and pharma.Read article - Patient support
GLP-1s, AI and the Informed Patient: Why Saudi Arabia Needs Continuous Care Now
AI-informed patients and GLP-1 therapies are changing care in Saudi Arabia. See why clinician-led support must continue between appointments.Read article